Any adverse events or reactions associated with cell salvage (autologous) transfusion methods,
including intraoperative cell salvage (ICS) and postoperative cell salvage (PCS) (washed or unwashed).
SHOT has collected stand-alone data on autologous transfusions since 2008. Prior to this, reports were included within other categories, for example IBCT or acute reactions. The original reporting category definition included incidents relating to acute normovolaemic haemodilution (ANH) and preoperative autologous donation (PAD) until 2017.
Cell-salvage devices are medical devices and as such any failures should be additionally reported to the appropriate regulatory authority responsible for monitoring medical device safety
Cell-salvage operators should be trained and have documented evidence of competency assessment. Organisations should review ongoing competence and institute re-training or update training as necessary to ensure patient safety
Cell salvage should be performed to standard protocols identified by the organisation to reflect best practice. Variations in practice to suit an individual patient’s circumstances should be discussed prior to intervention and risks and benefits considered
Cell-salvage operators and clinicians must be alert to unusual unpredictable events related to patient factors. Monitoring of the process in relation to quality of the reinfused product is just as important as monitoring the reinfusion itself
Organisations should consider whether a failure in provision of cell salvage, as a result of adverse event or logistics, puts a patient at risk of an avoidable allogeneic transfusion and report to SHOT accordingly
Organisations should ensure that clinical coding for cell salvage is used consistently (office of population censuses and surveys (OPCS) codes X36.4 and X33.7) to assist with establishing national denominator data